Dosimetry in peptide receptor Radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: Intra- and interpatient variability

被引：0
|
作者：
Wehrmann, C. [1 ]
Senftleben, S. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zentralklin Bad Berka GmbH, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2007年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S178 / S179
页数：2
相关论文
共 50 条
  • [31] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
    Geenen, Lorain
    Nonnekens, Julie
    Konijnenberg, Mark
    Baatout, Sarah
    De Jong, Marion
    Aerts, An
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 102 : 1 - 11
  • [32] Morphologic and metabolic response assessment of 177Lu-DOTA-TATE peptide receptor radionuclide therapy (PRRT) with 68Ga-DOTA-TOC PET/CT
    Gaertner, F. C.
    Hillerer, C.
    Lapa, C.
    Miederer, M.
    D'Alessandria, C.
    Wester, H.
    Schwaiger, M.
    Scheidhauer, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S267 - S267
  • [33] Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE in the treatment of malignant insulinoma: a case report of remarkable clinical and imaging response
    Barbosa, D.
    Duarte, H.
    Paula Santos, A.
    Ferro, J.
    Prospero, I.
    Silva, D.
    Gil-Santos, S.
    Calheiros, R.
    Fontao de Castro, S.
    Ferreira, G.
    Teixeira, P.
    Lucena Sampaio, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S219 - S219
  • [34] Absorbed Dose Values After Radionuclide Therapy with LU-177 DOTA TATE in Patients with Neuroendocrine Tumor
    Demir, M.
    Yeyin, N.
    Toklu, T.
    Uslu, L.
    Cavdar, I.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S515 - S515
  • [35] Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment (vol 66, pg 269, 2022)
    Mottaghi, Mahdi
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (04): : 587 - 587
  • [36] Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy
    E. Seregni
    M. Maccauro
    C. Chiesa
    L. Mariani
    C. Pascali
    V. Mazzaferro
    F. De Braud
    R. Buzzoni
    M. Milione
    A. Lorenzoni
    A. Bogni
    A. Coliva
    S. Lo Vullo
    E. Bombardieri
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 223 - 230
  • [37] Methodological Effects in Kidney Dosimetry in Lu-177 Radionuclide Therapy
    Heikkonen, J.
    Maenpaa, H.
    Tenhunen, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S265 - S265
  • [38] Lu-177 HA-DOTATATE for Peptide Receptor Radionuclide Therapy (PRRT): First Results in Patients Concerning Biodistribution, Normal Organ and Tumor Dosimetry
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S224
  • [39] Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy
    Seregni, E.
    Maccauro, M.
    Chiesa, C.
    Mariani, L.
    Pascali, C.
    Mazzaferro, V.
    De Braud, F.
    Buzzoni, R.
    Milione, M.
    Lorenzoni, A.
    Bogni, A.
    Coliva, A.
    Lo Vullo, S.
    Bombardieri, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (02) : 223 - 230
  • [40] Comparison of tumour and whole body absorbed doses of 177-Lu- DOTA-TATE and Lu-177 DOTA-NOC treatment in the same patient group
    Yeyin, N.
    Kabasakal, L.
    Akyel, R.
    Ocak, M.
    Toklu, T.
    Selcuk, N.
    Demir, M.
    Kanmaz, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S200 - S200
12345